Trial Profile
Phase I Clinical Study of RG3502 in Combination With RG1273 in Patients With Advanced or Recurrent HER2-Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jun 2016
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 03 Jun 2016 New trial record